| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 21 Oct 2026 |
Form 4: ADAR1 Capital Management, Llc, 10% owner and 1 other
Bought 336,528 shares ($507K) · Bought 254,342 shares ($406K) · Bought 331,979 shares ($551K) |
| 15 Oct 2026 | SCHEDULE 13G/A |
| 13 Oct 2026 | SCHEDULE 13G/A |
| 09 Oct 2026 | SCHEDULE 13G/A |
| 08 Oct 2026 |
8-K: Other Events
Forward-Looking Statements Disclaimers Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. These forward-looking statements include, but ar... |
| 17 Sep 2026 |
Form 4: Doogan Declan, Director
Bought 53,000 shares ($102K) |
| 15 Sep 2026 |
Form 4: Giordano Christopher Thomas, Director
Bought 6,000 shares ($11.3K) · Bought 4,850 shares ($8.84K) |
| 15 Sep 2026 |
Form 4: Staab Thomas R Ii, Chief Financial Officer
Bought 5,675 shares ($11K) |
| 11 Sep 2026 | SCHEDULE 13G/A |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
LEVEL Clinical Trial Results September 09, 2026 Exhibit 99.1 |
Loading...